Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

Condition:   Light Chain (AL) Amyloidosis, Stage 3B Interventions:   Drug: Daratumumab;   Drug: Bortezomib Injection;   Drug: Dexamethasone oral tablet Sponsors:   European Myeloma Network;   Janssen Pharmaceutica Not yet recruiting

Source: ClinicalTrials.gov - October 18, 2019 Category: Research Source Type: clinical trials